-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Previous studies of the new coronavirus have shown that the risk of neurological diseases is increased.
In fact, some reports indicate that survivors of COVID-19 are at increased risk of mood and anxiety disorders within 3 months of infection
Quantifying the relationship between SARS-CoV-2 infection and anxiety/depressive symptoms itself requires separating the consequences of infection from other factors (such as lockdown measures)
In addition, analysis of self-reported real-time data can help understand the impact of SARS-CoV-2 infection on mental health in a faster and timely manner
They evaluated the anxiety and depression symptoms of 413,148 people from February to April 2021; 26,998 people tested positive for SARS-CoV-2
Overall, 26.
The prevalence of anxiety and depression was slightly higher in the previous SARS-CoV-2 positive (30.
The research results are robust to multiple sensitivity analyses
The link between SARS-CoV-2 infection and anxiety and depression is stronger in the most recent (<30 days) and more distant (>120 days) infected persons, which indicates a short-term effect
The important significance of this research lies in the discovery: a small association was found between SARS-CoV-2 infection and symptoms of anxiety and depression
A small association was found between SARS-CoV-2 infection and symptoms of anxiety and depression
Leave a message here